Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics (TMDX) to $160 from $140 and keeps an Overweight rating on the shares. The firm notes Transmedics reported Q4 results that beat its key financial targets. Guidance for the year was good, especially on the revenue line where Piper believes upside may exist.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $152 from $148 at Canaccord
- Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating
- Closing Bell Movers: First Solar down 12% on earnings miss
- TransMedics reports Q4 EPS $2.62 with items, consensus 37c
- TransMedics sees FY26 revenue $727M-$757M, consensus $725.04M